Variable | Malignancies | Hematologic malignancies | ||
---|---|---|---|---|
Crude | Adjusted | Crude | Adjusted | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Age | 1.04 (1.03–1.05) | 1.04 (1.03–1.04) | 1.02 (0.99–1.06) | 1.02 (0.98–1.05) |
Male sex | 1.90 (1.59–2.27) | 1.88 (1.57–2.25) | 1.55 (0.59–4.07) | 1.41 (0.53–3.74) |
Comorbidities | 1.66 (1.39–1.99) | 1.34 (1.11–1.61) | 2.42 (0.87–6.73) | 2.29 (0.80–6.52) |
Medications | ||||
 bDMARD ever use | 0.41 (0.24–0.70) | 0.42 (0.25–0.73) | 1.91 (0.44–8.27) | 1.69 (0.38–7.59) |
 Methotrexate use | 0.90 (0.76–1.07) | 0.93 (0.78–1.12) | 1.21 (0.49–2.97) | 1.06 (0.41–2.74) |
 Corticosteroid use | 1.03 (0.86–1.25) | 1.05 (0.86–1.28) | 1.12 (0.40–3.11) | 1.02 (0.35–2.95) |
 NSAID use | 1.22 (0.88–1.71) | 1.16 (0.83–1.63) | 1.61 (0.22–12.09) | 2.00 (0.26–15.48) |